In the past year and a half, many organizations demonstrated herculean feats serving customers and pivoting to selling in a virtual world. They built production capacity, stood up new businesses, launched new products and deployed new marketing, sales and service motions. It was truly impressive to witness the agility and ingenuity of players in the space. The accomplishments of 2020/2021 notwithstanding, there is more work to be done.
The path to revenue growth has fundamentally changed. The industry will see a wave of accelerated growth over the next several quarters as companies continue their response to the world’s need for testing, vaccines and therapies. Commercial organizations need to be ready to take more than their fair share. Those that act quickly and decisively will cement their growth path.
So how are Life Sciences and Analytical Instruments companies planning for the coming three to five years after navigating a tumultuous 2020/2021?
Five emerging trends are shaping how commercial leaders deploy and direct their resources. The Alexander Group’s latest whitepaper explores these trends and the strategic priorities needed to enhance revenue growth and move forward into new territory.
1. Funding Shifts
2. New Customer Priorities
3. Emerging Customer Segments
4. Limited Lab Access
5. Changing Buyer Behaviors
Download the whitepaper to learn how leading industry players will revamp their strategic plans while executing on immediate term growth opportunities.
Topics discussed include:
For more information about Alexander Group’s Life Sciences and Analytical Instruments practice please contact a practice leader.